Ruthenium-Catalyzed Transformation of Aryl and Alkenyl Triflates to Halides
摘要:
Aryl triflates were transformed to aryl bromides/iodides simply by treating them with LiBr/NaI and [Cp*Ru(MeCN)(3)]OTf. The ruthenium complex also catalyzed the transformation of alkenyl sulfonates and phosphates to alkenyl halides under mild conditions. Aryl and alkenyl triflates undergo oxidative addition to a ruthenium(II) complex to form eta(1)-arylruthenium and 1-ruthenacyclopropene intermediates, respectively, which are transformed to the corresponding halides.
Pd‐Catalyzed Intermolecular Transthiolation of Ar‐OTf Using Methyl 3‐(Methylthio) Propanoate as a Thiol Surrogate
作者:Dandan Pan、Shasha Xu、Qingqiang Tian、Yahui Li
DOI:10.1002/ejoc.202100822
日期:2021.9.7
The work describes an intermoleculartransthiolation of Ar−OTf usingmethyl 3-(alkyllthio) propanoate as an odourless thiolsurrogate. A series of substituted aryl methyl sulfides have been obtained in moderate to good yields.
[EN] SHMT INHIBITORS AND USES THEREOF<br/>[FR] INHIBITEURS DE SHMT ET LEURS UTILISATIONS
申请人:RAZE THERAPEUTICS INC
公开号:WO2018106636A1
公开(公告)日:2018-06-14
The present invention provides compounds, compositions thereof, and methods of using the same.
本发明提供了化合物、其组合物以及使用它们的方法。
Inverting Conventional Chemoselectivity in the Sonogashira Coupling Reaction of Polyhalogenated Aryl Triflates with TMS-Arylalkynes
作者:Miao Wang、Chau Ming So
DOI:10.1021/acs.orglett.1c04138
日期:2022.1.21
Sonogashira couplingreaction with excellent chemoselectivity, affording an inversion of the conventional chemoselectivity order of C–Br > C–Cl > C–OTf. This study also provided an efficient approach to the synthesis of polycyclic aromatic hydrocarbons (PAHs) and the natural product analogue trimethyl-selaginellin L by merging of chemoselective Sonogashira and Suzuki–Miyaura couplingreactions.
This invention relates to compounds of formula (I) where R
1
to R
12
, —W—V—, —X—Y—, m and n have the values defined in claim
1,
their preparation and use as pharmaceuticals.
1
[EN] COMPOUNDS FOR BINDING PROPROTEIN CONVERTASE SUBTILISIN/KEXIN TYPE 9 (PCSK9)<br/>[FR] COMPOSÉS SE LIANT À LA PROPROTÉINE CONVERTASE SUBTILISINE/KEXINE DE TYPE 9 (PCSK9)
申请人:PORTOLA PHARM INC
公开号:WO2017147328A1
公开(公告)日:2017-08-31
The present disclosure relates to novel compounds, methods, and compositions capable of binding to PCSK9, thereby modulating PCSK9 proprotein convertase enzyme activity. The compounds of the disclosure include compounds Formula (I).